143 related articles for article (PubMed ID: 7616599)
1. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells.
Knick VC; Eberwein DJ; Miller CG
J Natl Cancer Inst; 1995 Jul; 87(14):1072-7. PubMed ID: 7616599
[TBL] [Abstract][Full Text] [Related]
2. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice.
Ashizawa T; Asada M; Kobayashi E; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Oct; 4(5):577-83. PubMed ID: 8292816
[TBL] [Abstract][Full Text] [Related]
3. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.
Budman DR; Calabro A; Wang LG; Liu XM; Stiel L; Adams LM; Kreis W
Cancer Invest; 2000; 18(8):695-701. PubMed ID: 11107439
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
[TBL] [Abstract][Full Text] [Related]
5. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Bissery MC; Vrignaud P; Lavelle F
Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer.
Chang AY; Garrow GC
Semin Oncol; 1995 Apr; 22(2 Suppl 5):66-70; discussion 70-1. PubMed ID: 7740336
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549).
Jung M; Grunberg S; Timblin C; Buder-Hoffman S; Vacek P; Taatjes DJ; Mossman BT
Histochem Cell Biol; 2004 Feb; 121(2):115-21. PubMed ID: 14745558
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines.
Photiou A; Shah P; Leong LK; Moss J; Retsas S
Eur J Cancer; 1997 Mar; 33(3):463-70. PubMed ID: 9155533
[TBL] [Abstract][Full Text] [Related]
10. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
Adams DJ; Knick VC
Invest New Drugs; 1995; 13(1):13-21. PubMed ID: 7499103
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Conte PF; Baldini E; Michelotti A; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Giannessi PG; Gentile A
Semin Oncol; 1996 Dec; 23(6 Suppl 15):39-42. PubMed ID: 8996597
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.
Waud WR; Gilbert KS; Harrison SD; Griswold DP
Cancer Chemother Pharmacol; 1992; 31(3):255-7. PubMed ID: 1361163
[TBL] [Abstract][Full Text] [Related]
16. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
19. Current status of vinorelbine for breast cancer.
Smith GA
Oncology (Williston Park); 1995 Aug; 9(8):767-73; discussion 774, 776, 779. PubMed ID: 7577376
[TBL] [Abstract][Full Text] [Related]
20. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.
Kiue A; Sano T; Naito A; Inada H; Suzuki K; Okumura M; Kikuchi J; Sato S; Takano H; Kohno K
Jpn J Cancer Res; 1990 Oct; 81(10):1057-64. PubMed ID: 1977728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
